472 related articles for article (PubMed ID: 15549188)
1. Current status of radiation therapy and combined-modality treatment for bladder cancer.
Rödel C
Strahlenther Onkol; 2004 Nov; 180(11):701-9. PubMed ID: 15549188
[TBL] [Abstract][Full Text] [Related]
2. Trimodality treatment and selective organ preservation for bladder cancer.
Rödel C; Weiss C; Sauer R
J Clin Oncol; 2006 Dec; 24(35):5536-44. PubMed ID: 17158539
[TBL] [Abstract][Full Text] [Related]
3. An update of combined modality therapy for patients with muscle invading bladder cancer using selective bladder preservation or cystectomy.
Shipley WU; Kaufman DS; Heney NM; Althausen AF; Zietman AL
J Urol; 1999 Aug; 162(2):445-50; discussion 450-1. PubMed ID: 10411054
[TBL] [Abstract][Full Text] [Related]
4. Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy: long term results.
Danesi DT; Arcangeli G; Cruciani E; Altavista P; Mecozzi A; Saracino B; Orefici F
Cancer; 2004 Dec; 101(11):2540-8. PubMed ID: 15481058
[TBL] [Abstract][Full Text] [Related]
5. Radiochemotherapy for bladder cancer.
Ott OJ; Rödel C; Weiss C; Wittlinger M; St Krause F; Dunst J; Fietkau R; Sauer R
Clin Oncol (R Coll Radiol); 2009 Sep; 21(7):557-65. PubMed ID: 19564101
[TBL] [Abstract][Full Text] [Related]
6. Management of superficial recurrences in an irradiated bladder after combined-modality organ-preserving therapy.
Weiss C; Wittlinger M; Engehausen DG; Krause FS; Ott OJ; Dunst J; Sauer R; Rödel C
Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1502-6. PubMed ID: 17935905
[TBL] [Abstract][Full Text] [Related]
7. Overview of bladder cancer trials in the Radiation Therapy Oncology Group.
Shipley WU; Kaufman DS; Tester WJ; Pilepich MV; Sandler HM;
Cancer; 2003 Apr; 97(8 Suppl):2115-9. PubMed ID: 12673704
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience.
Efstathiou JA; Spiegel DY; Shipley WU; Heney NM; Kaufman DS; Niemierko A; Coen JJ; Skowronski RY; Paly JJ; McGovern FJ; Zietman AL
Eur Urol; 2012 Apr; 61(4):705-11. PubMed ID: 22101114
[TBL] [Abstract][Full Text] [Related]
9. Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy?
Weiss C; Wolze C; Engehausen DG; Ott OJ; Krause FS; Schrott KM; Dunst J; Sauer R; Rödel C
J Clin Oncol; 2006 May; 24(15):2318-24. PubMed ID: 16710030
[TBL] [Abstract][Full Text] [Related]
10. Bladder preservation: optimizing radiotherapy and integrated treatment strategies.
Mak RH; Zietman AL; Heney NM; Kaufman DS; Shipley WU
BJU Int; 2008 Nov; 102(9 Pt B):1345-53. PubMed ID: 19035903
[TBL] [Abstract][Full Text] [Related]
11. The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?
Wo JY; Shipley WU; Dahl DM; Coen JJ; Heney NM; Kaufman DS; Zietman AL
BJU Int; 2009 Jul; 104(2):179-83. PubMed ID: 19154448
[TBL] [Abstract][Full Text] [Related]
12. The value of bladder-conserving strategies in muscle-invasive bladder carcinoma compared with radical surgery.
Merseburger AS; Kuczyk MA
Curr Opin Urol; 2007 Sep; 17(5):358-62. PubMed ID: 17762631
[TBL] [Abstract][Full Text] [Related]
13. Selective organ preservation in muscle-invasive bladder cancer: review of the literature.
Khosravi-Shahi P; Cabezón-Gutiérrez L
Surg Oncol; 2012 Mar; 21(1):e17-22. PubMed ID: 22088598
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy for muscle-invasive bladder cancer treated with definitive radiotherapy: persisting uncertainties.
Choueiri TK; Raghavan D
Nat Clin Pract Oncol; 2008 Aug; 5(8):444-54. PubMed ID: 18577983
[TBL] [Abstract][Full Text] [Related]
15. Organ-sparing strategies in the management of invasive bladder cancer.
Yafi FA; Cury FL; Kassouf W
Expert Rev Anticancer Ther; 2009 Dec; 9(12):1765-75. PubMed ID: 19954288
[TBL] [Abstract][Full Text] [Related]
16. Bladder-sparing, combined-modality approach for muscle-invasive bladder cancer: a multi-institutional, long-term experience.
Perdonà S; Autorino R; Damiano R; De Sio M; Morrica B; Gallo L; Silvestro G; Farella A; De Placido S; Di Lorenzo G
Cancer; 2008 Jan; 112(1):75-83. PubMed ID: 18008364
[TBL] [Abstract][Full Text] [Related]
17. Organ-sparing treatment in muscle-invasive bladder cancer.
Dunst J; Diestelhorst A; Kühn R; Müller AC; Scholz HJ; Fornara P
Strahlenther Onkol; 2005 Oct; 181(10):632-7. PubMed ID: 16220401
[TBL] [Abstract][Full Text] [Related]
18. Bladder-sparing therapy for muscle-infiltrating bladder cancer.
Pansadoro V; Emiliozzi P
Nat Clin Pract Urol; 2008 Jul; 5(7):368-75. PubMed ID: 18560383
[TBL] [Abstract][Full Text] [Related]
19. Bladder preservation in selected patients with muscle-invasive bladder cancer by complete transurethral resection of the bladder plus systemic chemotherapy: long-term follow-up of a phase 2 nonrandomized comparative trial with radical cystectomy.
Solsona E; Climent MA; Iborra I; Collado A; Rubio J; Ricós JV; Casanova J; Calatrava A; Monrós JL
Eur Urol; 2009 Apr; 55(4):911-9. PubMed ID: 18722046
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcome of radiation-based conservation therapy for invasive bladder cancer.
Chung PW; Bristow RG; Milosevic MF; Yi QL; Jewett MA; Warde PR; Catton CN; McLean M; Moore M; Tannock IF; Gospodarowicz MK
Urol Oncol; 2007; 25(4):303-9. PubMed ID: 17628296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
